<DOC>
	<DOCNO>NCT00954486</DOCNO>
	<brief_summary>The primary objective study assess ability epoetin alfa raise hemoglobin ( Hb ) level elderly outpatient unexplained anemia . The secondary objective study assess ability epoetin alfa improve physical function ; cognitive function ; quality life , assess safety epoetin alfa study population .</brief_summary>
	<brief_title>Erythropoietin Alfa Elderly Subjects With Unexplained Anemia</brief_title>
	<detailed_description>Eligible subject recruit companion study `` Anemia Elderly '' ( NCT00640172 ) , active participation study complete . Subjects full hematologic evaluation , unexplained anemia previously define . Subjects provide baseline physical function testing , include exercise testing treadmill test far patient walk 6 minute ( walk test ) , well quality life ; activity level ; mental functioning . Study visit weekly , dose level may adjust achieve target hemoglobin level within 16 week . Once target , drug take total 12 additional week . The maximum time study drug could 28 week , minimum time 14 week . The walk test questionnaire repeat target hemoglobin level reach , treatment complete . The test quality life , activity level , mental functioning repeated end treatment . Follow-up visit every 4 week 12 week check side effect .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>INCLUSION CRITERIA : Aged ≥ 65 Hb ≤ 11 g/dL Outpatient either VA Palo Alto Health Care Systems ( VAPAHCS ) Stanford Hospital Clinics ( SHC ) Independently live community ( ie , institutionalized living group home ) Ability understand willingness sign write informed consent document Performance level ECOG 2 good Diagnosis unexplained anemia EXCLUSION CRITERIA : Substance abuse mental health problem would affect compliance protocol Predicted mortality base comorbidities less 3 month On erythropoiesisstimulating agent prior 3 month Known HIV ; hepatitis B ; hepatitis C chronic infection Clinically significant uncontrolled medical condition consider high risk participation investigational study Serum albumin &lt; 3 g/dL Use investigational medication participation investigational study within 4 week prior enrollment trial Liver disease define total bilirubin ≥ 2 g/dL AST/ALT ≥ 2 time upper limit normal Allergy recombinant human erythropoietin Estimated glomerular filtration rate Modification Diet Renal Disease ( MDRD ) equation &lt; 30 mL/min/1.73 m2 dialysis History proximal deep venous thrombosis pulmonary embolism within past 12 month Known contraindication exercise test</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>